FDA approves a second Alzheimer’s drug shown to delay cognitive decline
6
![FDA approves a second Alzheimer’s drug shown to delay cognitive decline](https://images.fastcompany.com/image/upload/w_1280,q_auto,f_auto,fl_lossy/wp-cms-2/2024/07/AP24184513211915.jpg)
The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22% more slowly in terms of memory and cognitive ability.
U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment.